10-KPeriod: FY2023

CVS HEALTH Corp Annual Report, Year Ended Dec 31, 2023

Filed February 7, 2024For Securities:CVS

Summary

CVS Health Corporation (CVS) reported strong top-line growth in its 2023 10-K filing, with total revenues increasing by 10.9% year-over-year to $357.8 billion. This growth was driven by broad-based strength across all segments, notably the Health Services segment which saw a 10.2% revenue increase, bolstered by acquisitions like Oak Street Health and Signify Health. The company also highlighted continued investment in technology and strategic initiatives aimed at enhancing consumer experience and operational efficiency. Despite revenue growth, adjusted operating income saw a slight decrease of 2.7% to $17.5 billion, impacted by increased utilization in Medicare Advantage programs and ongoing competitive pressures within the PBM industry. Key strategic moves included the integration of Oak Street Health and Signify Health, positioning CVS Health to expand its primary care and value-based care capabilities. The company also saw a significant improvement in its Medicare Advantage star ratings for 2024, expected to positively impact future revenues. However, increased interest expenses due to debt financing for acquisitions and higher health care costs in the Health Care Benefits segment presented headwinds. Management remains focused on enterprise-wide cost savings and efficiency improvements to navigate these challenges and drive sustainable long-term growth.

Financial Highlights

56 data points
Beta

Revenue

$357.78B

39.3% Gross Margin

Net Income

$8.37B

2.3% Net Margin

EPS (Diluted)

$6.47

Total Assets

$249.73B

Cash & Equivalents

$8.20B

Free Cash Flow

$10.39B

Financial Statements
Beta
Revenue$357.78B
Cost of Revenue$217.10B
Gross Profit$140.68B
Operating Expenses$344.03B
Operating Income$13.74B
Interest Expense$2.66B
Net Income$8.37B
EPS (Basic)$6.49
EPS (Diluted)$6.47
Shares Outstanding (Basic)1.28B
Shares Outstanding (Diluted)1.29B

Key Highlights

  • 1Total revenues increased by 10.9% to $357.8 billion in 2023, driven by growth across all segments.
  • 2The Health Services segment revenue grew by 10.2%, significantly benefiting from the acquisitions of Oak Street Health and Signify Health.
  • 3Adjusted operating income decreased by 2.7% to $17.5 billion, impacted by increased Medicare Advantage utilization and PBM industry pressures.
  • 4The company's Medicare Advantage star ratings improved significantly for 2024, expecting to recover revenue losses from 2024 in 2025.
  • 5Interest expense increased by 16.2% due to higher debt levels to fund the recent acquisitions.
  • 6Net income attributable to CVS Health increased substantially by 93.6% to $8.3 billion, largely due to the absence of significant litigation charges recorded in the prior year.
  • 7CVS Health announced a 10% increase in its quarterly cash dividend, demonstrating a commitment to returning capital to shareholders.

Frequently Asked Questions

CVS Health's total revenues increased by 10.9% to $357.8 billion in 2023. This growth was driven by increased membership in Medicare Advantage, growth in the Health Services segment (particularly from the acquisitions of Oak Street Health and Signify Health), increased prescription volume and brand inflation in the Pharmacy & Consumer Wellness segment, and improved purchasing economics in the Health Services segment.

The acquisitions of Oak Street Health and Signify Health significantly contributed to the 10.2% revenue growth in the Health Services segment. These acquisitions are part of CVS Health's strategy to expand its primary care and value-based care capabilities. While they contributed positively to revenue, they also increased operating expenses due to amortization of intangible assets and integration costs, leading to a decrease in adjusted operating income for the Health Services segment.

CVS Health saw a significant improvement in its Medicare Advantage star ratings for 2024, with 87% of members in plans rated 4.0 stars or higher, compared to 21% in the prior year. This improvement, driven by a half-star increase in the Aetna National PPO plan, is expected to lead to eligibility for bonus payments in 2025, recovering the majority of the revenue decrease experienced in 2024. The company plans to reinvest a portion of this improvement back into the business.

Key challenges include increased health care costs and utilization in the Health Care Benefits segment, particularly within Medicare Advantage programs, which outpaced pricing adjustments. Competitive pressures in the PBM industry continue to impact margins as the company shares more rebates with clients. Additionally, increased interest expenses due to higher debt levels from acquisitions and ongoing retail pharmacy reimbursement pressures were notable headwinds.